Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer.

A MatroneA PreteA NervoA RagniL AgateE MolinaroC GianiL ValerioE MinaldiA PiovesanRossella Elisei

Published in: Journal of endocrinological investigation (2021)

In this real-life clinical experience, lenvatinib showed interesting results as salvage therapy in patients with advanced progressive metastatic MTC patients. Its usefulness could be effective in patients without any other available treatment, because previously used or unsuitable, especially with negative RET status with no access to the new highly selective targeted therapies.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
small cell lung cancer
prognostic factors
multiple sclerosis
stem cells
patient reported outcomes
bone marrow